Clinical Trials Logo

Waldenstrom's Macroglobulinemia clinical trials

View clinical trials related to Waldenstrom's Macroglobulinemia.

Filter by:

NCT ID: NCT00142155 Completed - Clinical trials for Waldenstrom's Macroglobulinemia

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

Start date: January 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

NCT ID: NCT00142129 Completed - Clinical trials for Lymphoplasmacytic Lymphoma

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.

NCT ID: NCT00142116 Completed - Clinical trials for Lymphoplasmacytic Lymphoma

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Start date: May 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and thalidomide in people with lymphoplasmacytic lymphoma.